The three options for payment are as follows:

  1. Credit card payment online
  2. Payment via cheque
  3. Third-party payment via cheque or credit card

If paying by cheque, you will need to print the confirmation and mail it to us with payment. Further instructions and the mailing address will be provided in the confirmation email.

Please note: Under the new incorporated CAPRA, credits for meetings can no longer be issued. In order to attend a dinner meeting, payment must be received prior to the meeting (either by mail in advance of the meeting or in person at the registration desk). Please be advised that cheques should not be mailed less than a week prior to the meeting. Registrants for whom payment has not been received will be refused entry to the meeting.


Add the "Buy Tickets" option to your cart. After completing the checkout process, you will be provided with a link to the Event Registration form(s) where you can provide us with the details of the attendee(s). If you have registered for previous events, then you can simply confirm your previously submitted details, or make changes where needed.

Montreal Dinner meeting

Date: Monday, June 18, 2018
Place: Sheraton Montreal Airport Hotel, 
555 Boulevard McMillan, Dorval, Quebec
Time: Registration and reception: 5:30-6:00 pm 
Presentation: 6:00-7:15 pm 
Dinner: 7:15-8:30 pm

Dinner Meeting Title: ICH Q12 – Challenges, Opportunities … and more Challenges.  

Description: A perspective will be provided on the aspirations, issues, challenges and opportunities associated with development and eventual implementation of the ICH Q12 guideline.  Elements will include: the value of risk-rationalized categorization of communication with the regulator; “Established Conditions” and their potential for leveraging “regulatory relief”; Post-Approval Change Management Protocols; and the potential for Q12 to have significant value beyond current ICH.  

Speaker: Anthony Ridgway, Ph.D.
Senior Regulatory Scientist
Centre for Evaluation of Radiopharmaceuticals and Biotherapeutics
Biologics and Genetic Therapies Directorate

Dr. Ridgway completed his Ph.D. at McGill University in Montreal and then proceeded to post-doctoral studies followed by an Assistant Professorship in the Cancer Research Laboratory and Department of Microbiology and Immunology at the University of Western Ontario.  Academic research activities included work on the structure and expression of oncogenes, retroviral and HIV regulatory elements, and inducible expression vectors.  He has been with Health Canada since 1991 and, in 1999, became manager of the Biotherapeutics Division, with responsibility for regulation of a wide range of products.  In 2004 he guided the separation of his former division into three new divisions and assumed the new position of Senior Regulatory Scientist in the Office of the Director, in the newly formed Centre for Evaluation of Radiopharmaceuticals and Biotherapeutics (CERB), where he holds a range of supervisory and advisory responsibilities.  From September 2016 to April 2018, Dr. Ridgway served as the Acting Centre Director.  He has been active with the ICH* since 1993, serving on Expert Working Groups addressing the quality of biotechnology products and is currently the Health Canada Topic Lead on the Q12 EWG.  He has been active on consecutive US Pharmacopoeia Committees of Experts, since June 2000.  Dr. Ridgway has been extensively involved in the Canadian approach to Subsequent-entry Biologics (biosimilars), and the drafting and dissemination of Canadian guidance.  (*International Council on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use)

Date:Monday, June 18, 2018
Place:Sheraton Montreal Airport Hotel
555 Boulevard McMillan
Dorval, Quebec
Time:Registration and reception: 5:30-6:00 pm
Presentation: 6:00-7:15 pm
Dinner: 7:15-8:30 pm
Registration Deadline: Tuesday, June 12, 2018 4pm
Reservations or cancellations cannot be accepted after the deadline.